There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), Abeona Therapeutics (NASDAQ:ABEO) and Mesoblast Ltd (NASDAQ:MESO) with bullish sentiments.
ACADIA Pharmaceuticals Inc (ACAD)
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on ACADIA Pharmaceuticals Inc, with a price target of $60. The company’s shares closed yesterday at $19.11.
Fein commented:
“Valuation and risks to achievement of the target price. Our $60 PT is based on an equally weighted composite of: (a) $69/share, as a 35x multiple of taxed and diluted FY22 GAAP EPS of $4.09 discounted back to and (b) an NPV of $50/share (discount rate 10%, growth rate 2.5%).”
According to TipRanks.com, Fein is a 4-star analyst with an average return of 5.4% and a 45.9% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, Strongbridge Biopharma Plc, and Cyclacel Pharmaceuticals.
ACADIA Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $32.50, representing a 70.1% upside. In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $25 price target.
.
See today’s analyst top recommended stocks >>
Abeona Therapeutics (ABEO)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Abeona Therapeutics, with a price target of $30. The company’s shares closed yesterday at $14.
Selvaraju observed:
“Valuation methodology, risks and uncertainties. We ascribe a total risk-adjusted net present value (rNPV) of $1.46B to Abeona’s technology platforms, which yields a price per share of $30.00 based on about 50M shares outstanding as of end-2Q 2019. We utilize an 85% probability of success for EB-101. Risks include, but are not limited to: (1) slower-than-anticipated clinical trial progress; (2) trial failures; (3) slower-than-projected timelines for drug approvals; and (4) poor uptake of the firm’s products once introduced.”
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 3.7% and a 45.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Abeona Therapeutics with a $31.75 average price target.
Mesoblast Ltd (MESO)
In a report released today, Jason Kolbert from H.C. Wainwright maintained a Buy rating on Mesoblast Ltd, with a price target of $17. The company’s shares closed yesterday at $6.63.
Kolbert wrote:
“Our valuation is based on our therapeutic models and reflects our assumptions for the product launch dates, product attributes, and pricing, to determine the future revenue streams. We have not yet factored in China.”
According to TipRanks.com, Kolbert ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -3.5% and a 38.9% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Cytori Therapeutics Inc, Anavex Life Sciences, and Coherus Biosciences.
Mesoblast Ltd has an analyst consensus of Strong Buy, with a price target consensus of $18, implying a 171.5% upside from current levels. In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $16 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
